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The antigen-presenting molecule MR1 presents riboflavin-based
metabolites to Mucosal-Associated Invariant T (MAIT) cells. While
MR1 egress to the cell surface is ligand-dependent, the ability of
small-molecule ligands to impact on MR1 cellular trafficking re-
mains unknown. Arising from an in silico screen of the MR1 ligand-
binding pocket, we identify one ligand, 3-([2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl]formamido)propanoic acid, DB28, as well
as an analog, methyl 3-([2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-
yl]formamido)propanoate, NV18.1, that down-regulate MR1 from
the cell surface and retain MR1 molecules in the endoplasmic re-
ticulum (ER) in an immature form. DB28 and NV18.1 compete with
the known MR1 ligands, 5-OP-RU and acetyl-6-FP, for MR1 binding
and inhibit MR1-dependent MAIT cell activation. Crystal structures
of the MAIT T cell receptor (TCR) complexed with MR1-DB28 and
MR1-NV18.1, show that these two ligands reside within the A′-
pocket of MR1. Neither ligand forms a Schiff base with MR1 mol-
ecules; both are nevertheless sequestered by a network of hydro-
phobic and polar contacts. Accordingly, we define a class of
compounds that inhibits MR1 cellular trafficking.
Mucosal-Associated Invariant T (MAIT) cells are a subset ofevolutionarily conserved nonmajor histocompatibility
complex (MHC)-restricted T cells, which are very abundant in
human mucosal tissues, in peripheral blood, and in the liver (1,
2). Similar to type I NKT cells, human MAIT cells express a
semi-invariant T cell receptor (TCR) composed of the Vα7.2
chain rearranged mainly to Jα33 and paired with a limited
number of Vβ chains, mostly TRBV6, TRBV13, and TRBV20
(3, 4). MAIT cells recognize small microbial metabolites pre-
sented by the monomorphic MHC class I-related molecule, MR1
(1, 2). The physiological roles of MAIT cells remain unclear, but
they are known to be involved in protective immunity (2, 5–7),
possibly through modulation of innate and adaptive immune
responses (8, 9). Moreover, the role of MAIT cells in cancer (10)
and inflammatory diseases, such as obesity (11), diabetes (12),
multiple sclerosis (13), and inflammatory bowel disease (14), has
been highlighted, and recent reports have suggested they may
also play a role in tissue repair (15, 16). Activation of MAIT cells
induces the production of various proinflammatory cytokines,
predominantly IFN-γ, TNF-α, IL-2, and IL-17 (17, 18), and their
potent cytolytic activity allows them to kill infected cells (19).
Unlike MHC molecules, MR1 does not constitutively present
antigens, but is found in the endoplasmic reticulum (ER) of all
cells in a ligand-receptive conformation (20). The potency of
known MAIT cell agonists appears to correlate with their
ability to form a Schiff base with MR1 Lys43 located within the
A′-pocket, thus allowing MR1 to egress to the cell surface,
where the presence of a ribityl moiety in the covalently bound
agonist allows for an interaction with the MAIT TCR (21–23).
To date, the strongest MAIT cell agonists are 5-(2-oxopropyli-
deneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-(2-oxoethylide-
neamino)-6-D-ribitylaminouracil (5-OE-RU), both pyrimidine-based
intermediates along the riboflavin biosynthetic pathway (24). Several
bacterial and fungal species synthesize riboflavin (23), and MAIT cells
have been shown to possess MR1-dependent antimicrobial activity
against infected antigen-presenting cells (5, 6). Conversely, vitamin B9
metabolites [including the folic acid derivative 6-formylpterin, 6-FP and
its acetylated derivative Ac-6-FP (23, 25)] are strong MR1 binders and
induce MR1 expression at the cell surface; however, the resulting
complexes do not activate MAIT cells because they lack the ribityl
moiety (22). Drug and drug-like molecules (including diclofenac and
salicylates) also bind MR1 and either weakly activate or inhibit
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MAIT cells (26). However, it remains unknown whether there are
other ligands that impact MR1-dependent antigen presentation.
Through an in silico screen, we have identified additional
MR1-binding ligands. We describe a ligand that down-regulates
MR1 cell-surface expression and provide a molecular basis for its
interactions with MR1.
Results
Identification of Nonmicrobial MAIT Cell Agonists. To identify MR1
binding ligands, we performed in silico screening using the
crystal structures of the MAIT TCR in complex with MR1–
antigen complexes [PDB codes 4L4V and 4LCC (22, 27)]. A
total of 44,022 compounds were selected for docking runs, based
on searches for fragment size substructures s1-s20 (SI Appendix,
Fig. S1 and Supplementary Methods). Compound selection and
constraints imposed during docking are detailed in the supple-
mentary methods. Using this strategy, 80 commercial compounds
were selected as potential MR1 ligands, of which 52 compounds
were pulsed on MR1 overexpressing cells, alongside the canon-
ical MAIT cell ligand 5-OP-RU, synthesized and validated in
house (SI Appendix, Fig. S2 A and B). MAIT cell stimulatory
activity was observed when THP1-MR1 cells (Fig. 1A and SI
Appendix, Fig. S4A) were pulsed with compounds DB5, DB7,
DB8, DB12, DB15, DB19, and DB23, whose chemical structures
are shown in SI Appendix, Fig. S3. Overall, these compounds
were three to nine times less potent than 5-OP-RU (SI Appendix,
Fig. S4A). Unlike Ac-6-FP and 5-OP-RU (26), none of the tested
compounds induced detectable up-regulation of cell-surface
MR1, neither after 5 nor 22 h (Fig. 1B). Presentation was
MR1-dependent, as determined using the blocking anti-MR1
26.5 monoclonal antibody (28) (Fig. 1C) and pulsing the com-
pounds on MR1-KO THP1 cells (SI Appendix, Fig. S4B). Con-
sistent with their weaker potency, presentation by THP1 cells
required a higher level of MR1 expression (THP1-MR1 WT),
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Fig. 1. MAIT cell stimulation by the DB series of agonists. (A) THP1-MR1 cells were pulsed with the indicated compounds (100 μM MG, 20 μg/mL DB com-
pounds, 50 ng/mL 5-OP-RU) and incubated with MAIT cells. IFN-γ was measured in the supernatant after 36 h of coculture. Box and whiskers bars, minimum to
maximum, with all points indicated; n = 5. (B) The DB series of MAIT cell agonists do not induce MR1 up-regulation. THP1-MR1 cells were pulsed 5 or 22 h with
20 μg/mL of the indicated compounds, 100 μM MG, 1 μg/mL Ac-6-FP, or 1 μg/mL 5-OP-RU. Depicted is the cell surface expression of MR1 at 5 h (black bars) or
22 h (white bars) measured by FACS. Data are mean ± SD of technical duplicates. One experiment is representative of two. (C) MR1-dependent presentation
of the DB series of agonists. THP1-MR1 cells were pulsed with the indicated compounds (100 μMMG, 20 μg/mL for DB compounds, 50 ng/mL for 5-OP-RU) and
incubated with MAIT cells in the presence of isotype control or blocking anti-MR1 antibodies. IFN-γ was measured in the supernatant after 36 h of coculture.
Data are mean ± SD of technical duplicates. One experiment is representative of two. (D) DC were pulsed with the indicated compounds (100 μMMG, 20 μg/
mL DB compounds, 50 ng/mL 5-OP-RU) and incubated with MAIT cells. IFN-γ was measured in the supernatant after 36 h of coculture. Average from technical
duplicates from three different donors. One experiment is representative of two. (E) Ex vivo MAIT cell activation by the DB series of agonists. Whole blood
was stimulated overnight with the indicated compounds. MAIT cell activation, depicted as percentage of CD137 expression, was assessed by flow cytometry.
Box and whiskers bars, minimum to maximum, with all points indicated; n = 7. (F) TCRβ chain expression influences reactivity to DB MAIT cell agonists.
MAIT cells expressing TRBV20.1, TRBV13S2, and neither of those two chains (DN) were sorted from a single donor and incubated with THP1-MR1 pulsed with
the indicated compounds (100 μMMG, 20 μg/mL for DB compounds, 50 ng/mL for 5-OP-RU). UP, unpulsed. IFN-γwas measured in the supernatant after 36 h of
coculture. Data are mean ± SD of technical duplicates. One experiment is representative of two.
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whereas THP1 cells nonoverexpressing MR1 were unable to
present any of the DB compounds (SI Appendix, Fig. S4B). In
addition, presentation was reduced or abrogated when THP1
cells expressing GPI-linked molecules were used (SI Appendix,
Fig. S4B), suggesting internalization and possibly endo-lysosomal
loading is required. However, we were unable to detect any
MAIT cell activation by fixed THP1-MR1, even after pulsing
with the potent agonist 5-OP-RU; therefore, we did not in-
vestigate intracellular trafficking further. Compounds DB5,
DB12, and DB19 were also presented by monocyte-derived
dendritic cells (Fig. 1D). In this experimental setting,
MAIT cell activation was also MR1-dependent (SI Appendix,
Fig. S4C). We next tested the compounds on unfractionated cells
in whole blood and identified MAIT cells by Vα7.2 and
CD161 co-staining. MAIT cell activation (measured by CD137
up-regulation) with compounds DB7, DB8, DB12, and DB19
was observed in some, but not all, of the seven donors tested
(Fig. 1E); this may reflect pairing of different ΤCR β-chains with
the canonical MAIT TCR α-chain (3). Indeed, in one donor, we
observed a lower response by MAIT cells expressing the
TRBV13S2 chain as compared with the TRBV20.1 chain or
neither of those two chains (Fig. 1F). We also confirmed TCR-
mediated recognition of some of the DB compounds using
Jurkat cells transduced with a MAIT TCR composed of the
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Fig. 2. Characterization of DB28. (A) Chemical structures of the MR1 ligands used in this study: 5-OP-RU, 6-FP, DB28, and NV18.1. (B–D) DB28 and
NV18.1 down-regulate MR1 from the cell surface. (B) THP1-MR1 cells were pulsed for 5 or 22 h with the indicated ligands (MG 50 μM, Ac-6-FP 1 μg/mL,
5-OP-RU 5 μg/mL, DB28 20 μg/mL) before staining with anti-MR1 (26.5) antibody. (C) THP1-MR1 cells pulsed overnight with DMSO or DB28 (20 μg/mL) were
stained with the two indicated anti-MR1 antibodies. (D) THP1-MR1 (Left) or C1R-MR1 (Right) were pulsed overnight with the indicated concentrations of
DB28 or NV18.1 before staining with anti-MR1 (26.5) antibody. Geo MFI ± SD of technical duplicates are plotted in each graph. Data representative of three
experimental replicates.
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canonical TCR α-chain paired with TRBV20.1 or 6.4 (SI Ap-
pendix, Fig. S4 D and E) (29). In conclusion, we have defined a
series of compounds that bind MR1 and can activate, through
MR1-TCR interaction, MAIT cells expressing a variety of TCR
β chains.
DB28 Down-Regulates Cell Surface Expression of MR1. When testing
the 52 compounds for ligand-induced MR1 up-regulation, we
noticed that, unlike Ac-6-FP and 5-OP-RU, which potently up-
regulate MR1 cell-surface expression (24, 25), compound DB28
(3-[(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)formamido]prop-
anoic acid, Fig. 2A) not only failed to up-regulate MR1 at the
cell surface of THP1-MR1 cells but also reduced its expression
to almost background levels of staining, using the anti-MR1
monoclonal antibody 26.5 (Fig. 2B). The structural formula of
compound DB28, and its ester derivative NV18.1 (methyl 3-
[(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)formamido]prop-
anoate), are shown in Fig. 2A. 5-OP-RU and Ac-6-FP covalently
bind within the MR1 A′-pocket by forming a Schiff base with
MR1 Lys43 (24, 25), which triggers MR1 egress from the ER and
trafficking to the cell surface (20). DB28 has a terminal car-
boxylic acid, while the NV18.1 is its methyl ester analog; thus,
without undergoing reduction, neither is able to form a Schiff
base with MR1. Cell-surface MR1 down-regulation by DB28 and
NV18.1 was observed with two different conformation-specific
MR1 antibodies, 26.5 and 8F2.F9 (30, 31) (Fig. 2C), where
NV18.1 was less potent than DB28 (Fig. 2D). MR1 down-
regulation was observed when the compounds were tested in
both myeloid cells (THP1-MR1) and EBV-transformed B cells
(C1R-MR1) (Fig. 2D). The effect was specific for MR1, as no
down-regulation of MHC-I or CD1d molecules was observed at
the surface of THP1 cells (SI Appendix, Fig. S5).
The MR1 transcript is ubiquitous, but expression on primary
cells is low (32, 33). Nevertheless, we observed down-regulation
of basal and 5-OP-RU-induced surface expression of MR1 by
DB28 in primary B cells and monocytes freshly isolated from
four healthy donors (Fig. 3), confirming results previously
obtained with THP1 cells overexpressing MR1.
We next tested whether DB28 inhibits the up-regulation of
MR1 induced by other ligands. As shown in Fig. 4 A and B,
DB28 abrogated Ac-6-FP- or 5-OP-RU-induced up-regulation of
MR1 surface expression, and this effect was stronger when DB28
was in molar excess, suggesting competition for MR1 binding.
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Fig. 4. DB28 competes with 5-OP-RU for MR1 binding. (A and B) THP1-MR1
cells were pulsed with 20 μg/mL DB28 for 2 h before addition of the in-
dicated concentrations of Ac-6-FP (A) or 5-OP-RU (B). Cells were stained after
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before staining with anti-MR1 (26.5) antibody. Geo MFI ± SD of technical
duplicates are plotted in each graph. Data (A–C) are representative of three
experimental replicates. (D) THP1-MR1 cells were pulsed with 20 μg/mL DB28
and MG or 5-OP-RU in the presence (hatched bars) or absence (black bars) of
10 μM cycloheximide (CHX) to block protein synthesis. Plotted is the per-
centage of MR1 down-regulation for each experimental condition (n = 4
experimental replicates for MG, 3 for 5-OP-RU; multiple t test, **P ≤ 0.005).
(E) MR1-GFP expression was induced in BEAS2B cells with doxycycline; after
16 h, cells were pulsed with DB28 (20 μg/mL) for 8 h in the presence or ab-
sence of doxycycline. Geo MFI ± SD of surface MR1 expression (Left) or
percentage of MR1 down-regulation (Right) are plotted. n = 5 experimental
replicates with doxycycline, 3 without (t test, n.s).
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We added DB28 either concurrently with, 2 h before, or 2 h after
5-OP-RU. In all cases, DB28 reduced MR1 cell surface expres-
sion. This effect was reversible, since it persisted as long as DB28
was kept in culture for the duration of the assay and not washed
away after the first 5 h (Fig. 4C). The reversibility of the DB28
effect prompted us to investigate the contribution of protein
synthesis, which is not required for ligand-induced up-regulation
of MR1 surface expression (20). At steady state, DB28 down-
regulated surface expression of 90% of MR1 molecules, whereas
only 60% of MR1 molecules were down-regulated in the pres-
ence of the protein synthesis inhibitor cycloheximide. Likewise,
in the presence of 5-OP-RU, DB28 down-regulated 70% of MR1
molecules, but only 50% when cells were also treated with cy-
cloheximide (although this difference did not reach statistical
significance, Fig. 4D). To avoid potential off-target effects of
cycloheximide, we tested the epithelial cell line BEAS2B
expressing a tetracycline-inducible MR1 construct tagged with
GFP (34, 35). Upon doxycycline treatment, more than 90% of
cells became GFP positive and 10% to 15% of cells expressed
cell surface MR1 (SI Appendix, Fig. S6). There was a trend to-
ward lower MR1 down-regulation in the absence of doxycycline;
however, it did not reach statistical significance (Fig. 4E). In
conclusion, we observed selective down-regulation of MR1 cell
surface expression by DB28 and NV18.1, which was only mar-
ginally affected by blocking protein synthesis.
Requirements for DB28 Down-Modulation of MR1 Expression. As
previously shown (20), the Lys43Ala mutation facilitates the
release of MR1 molecules from the ER even in the absence of
vitamin B metabolites. To dissect the molecular mechanism by
which DB28 induces MR1 down-regulation, we generated THP1
cells expressing Lys43Ala-mutated MR1 molecules (SI Appendix,
Fig. S7) (20). For these experiments, we used MR1 KO THP1
cells (36) to avoid residual activity of WT MR1 molecules on
Lys43Ala MR1-bound ligands. MR1-Lys43Ala molecules were
insensitive to DB28-induced modulation, suggesting intracellular
retention rather than down-regulation from the cell surface as
the main mechanism for DB28-dependent MR1 down-regulation
(Fig. 5A). To investigate the role of the transmembrane and
cytoplasmic domains of MR1 in DB28 modulation of MR1 ex-
pression, we transduced THP1 MR1 KO cells with lentiviral
particles encoding for GPI-linked MR1 molecules (SI Appendix,
Fig. S7). Cell surface expression of GPI-linked MR1 molecules
was reduced in the presence of DB28, suggesting that the
transmembrane and cytoplasmic domains are not required for
the observed effect (Fig. 5B).
DB28 Retains MR1 in the ER in an Immature Form. To investigate the
fate of MR1 on incubation of cells with the ligand DB28, we
fixed and permeabilized the cells to determine total MR1 con-
tent by flow cytometry. Staining with a polyclonal anti-MR1
antibody revealed the total MR1 content was unaffected, thus
ruling out degradation of MR1 molecules (Fig. 6A); this was
further confirmed with the epithelial cell line, BEAS2B,
expressing a tetracycline-inducible MR1 construct tagged with
GFP (34, 35) or constitutively expressing GFP-tagged MR1
molecules. In both cell lines, in the presence of DB28, we ob-
served down-regulation of MR1 from the cell surface (Fig. 4E
and SI Appendix, Fig. S6B, respectively), but the total GFP
content remained unaffected (Fig. 6B and SI Appendix, Fig. S6C,
respectively). Consistent with these findings, when we sampled
the intracellular distribution of MR1 molecules by confocal mi-
croscopy, in the presence of vehicle, MR1 molecules were
preferentially colocalized within the ER and Golgi compart-
ments, as previously reported, while they translocated to the cell
surface with Ac-6-FP (20) (Fig. 6C and SI Appendix, Fig. S8A). In
contrast, in the presence of DB28, they remained in the ER/
Golgi compartments. Furthermore, MR1 molecules immuno-
precipitated with 26.5 antibody [which recognizes folded MR1
molecules (28)] remained EndoH sensitive in the presence of
DB28, as expected from their ER localization. In the presence of
5-OP-RU, they acquired partial EndoH resistance, which was
abrogated by coincubation with DB28 (Fig. 6D and SI Appendix,
Fig. S8B). In conclusion, DB28 retains the immature form of
MR1 within the ER.
DB28 Prevents MAIT Cell Activation by Agonist Ligands. Upon rec-
ognition of their cognate antigen via the TCR, MAIT cells re-
lease cytokines in an MR1-dependent manner (6, 19). In
agreement with a lack of effect of DB28 on CD1d expression (SI
Appendix, Fig. S5), iNKT cell activation was unaffected when
THP1 cells were pulsed with αGalCer and DB28 (SI Appendix,
Fig. S9A). Consistent with the ability of DB28 to down-regulate
MR1 cell surface expression even in the presence of MAIT cell
agonists (Fig. 4B), we observed dose-dependent inhibition of
MAIT cell activation when DB28 was pulsed on THP1-MR1
cells with an agonist ligand (Fig. 7 A and B). Likewise, pre-
sentation of vitamin B metabolites by epithelial cells infected
with bacillus Calmette-Guérin (Fig. 7C and SI Appendix, Fig.
S9B) or by peripheral blood mononuclear cells (PBMC) in-
fected with Escherichia coli (Fig. 7D and SI Appendix, Fig. S9C)
was significantly reduced in the presence of DB28. This effect
was specific to MR1-dependent stimulation, as activation of
MAIT cells with phytohemagglutinin was not affected by DB28
(Fig. 7C and SI Appendix, Fig. S9B), nor was activation of by-
stander CD161neg T cells upon bacterial exposure (SI Appendix,
Fig. S9D). We confirmed that even in bacillus Calmette-Guérin-
infected BEAS2B epithelial cells (SI Appendix, Fig. S10 A and
B) and E. coli-infected myeloid cells (THP1; SI Appendix, Fig.
S10 C and D), DB28 down-regulated cell surface MR1 (SI
Appendix, Fig. S10 A and C), but not total MR1 (SI Appendix, Fig.
S10 B and D).
MR1 molecules are highly evolutionarily conserved, with 90%
sequence homology between the α1 and α2 domains of hu-
mans and mice (32). In vitro experiments with murine bone
marrow-derived DC confirmed the ability of DB28 to inhibit
MR1-dependent human MAIT cell activation (SI Appendix,
Fig. S11A). We next injected i.v. DB28 to assess its effect on
5-OP-RU-dependent in vivo MAIT cell activation (SI Appendix,
Fig. S11B). Despite a 9 to 90 range of molar excess of DB28,
we did not observe inhibition of MAIT cell activation, which we
hypothesize might be a consequence of the rapid clearance of
the compound, as it does not form a Schiff base with MR1
molecules.
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In conclusion, these results demonstrate that, in vitro, DB28
acts as a competitive inhibitor for MAIT cell-activating ligands.
MR1-DB28 and MR1-NV18.1 Display Very Weak Binding to MAIT TCRs.
We next measured the binding affinity of MR1 loaded with
5-OP-RU, Ac-6-FP, DB28, and NV18.1 ligands toward two
MAIT TCRs (A-F7 [TRAV1-2-TRBV6-1] and #6 [TRAV1-2-
TRBV6-4] TCRs) (25), using surface plasmon resonance (SPR;
Fig. 8). As previously reported (25), the 5-OP-RU agonist
exhibited affinities to MAIT TCRs ranging from ∼3 to 10 μM,
whereas the folate antagonist Ac-6-FP showed weak binding
(97.4 ± 30.6 and 235 ± 67.7 μM to A-F7 and TRBV6-4 TCRs,
respectively) (24, 25). Consistent with the absence of the ribityl
tail and the lack of MAIT cell activation, both DB28 and NV-
18.1 revealed extremely low binding to AF-7 TCR (KD = 172.0 ±
36.7 and 200.0 ± 64.0 μM, respectively), while we could not
measure binding to TRBV6-4 TCR (KD = ND). Collectively, even
if the MR1 complexes with inhibitors DB28 and NV18.1 made it
to the cell surface, they would exhibit very weak affinities to MAIT
TCRs, in agreement with their inability to stimulate MAIT cells.
Crystal Structures of MR1-DB28 and MR1-NV18.1 Complexes Bound to
MAIT TCR. To gain insight into the molecular basis underpinning
MR1 down-regulation by DB28 and NV18.1, and despite the
very low affinity of the interaction, as judged by SPR, we were
able to crystallize the MAIT A-F7 TCR-MR1-DB28 and TCR-
MR1-NV18.1 complexes, consistent with other structural reports
with low-affinity ligands (26, 37). Both ternary structures were
determined at 2-Å resolution and exhibited unambiguous elec-
tron densities within the MR1-antigen binding cleft and at the
TCR-MR1-Ag interfaces (SI Appendix, Table S2 and Fig. 9). The
overall topology of the two ternary complexes was very similar,
whereby the MAIT TCR docks centrally above the MR1-antigen
binding cleft, but with a little juxtapositioning of the TCR
β-chain toward the F′ pocket compared with the TCR-MR1-
5-OP-RU structure (PDB: 6PUC) (22, 37); this was accompanied
by displacements and conformational changes within the Comple-
mentarity Determining Regions (CDR) loops of the TCR β-chain
(CDRβ), while the CDR loop positions within the TCR α-chain
were similar (Fig. 9 A and B).
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As expected from their chemical compositions, neither DB28
nor NV18.1 forms a Schiff base with Lys43 of MR1; however,
both ligands are clearly visible in the A′-pocket of MR1, as
evidenced by unbiased omit maps of the ligands (Fig. 9 C and D),
indicating strong sequestering of the ligands within the MR1
antigen-binding cleft. Here, the carbonyl group of the uracil ring
of both ligands is H-bonded to Lys43, which results in Lys43
being positioned closer to the ring structure when compared with
that of 5-OP-RU bound to MR1 (Fig. 9E). In addition, the uracil
ring of DB28 and NV18.1 adopts a position reminiscent of the
ring structure of 5-OP-RU (Fig. 9 F–H), whereby its positioning
is largely governed by a network of contacts that include hy-
drophobic interactions with the MR1 aromatic cradle (Tyr7,
Tyr62, Trp69, Ile96, and Trp156), as well as H-bonding to Lys43,
Arg9, and Ser24 residues (Fig. 9 F and G). Interestingly, the ori-
entation of the side-chain appendages of DB28 and NV18.1 within
the A′-pocket differ from that of 5-OP-RU: both side-chains are
constrained by an intramolecular H-bond between the amide NH
of the side-chain and the carbonyl oxygen of the carboxylic acid (in
DB28) or ester (in NV18.1; Fig. 9 F and G). This tilted confor-
mation of the ligands’ side-chains is supported by hydrophobic
interactions with Ile96, Trp69, and Trp156 residues, and H-bonding
with the Tyr152 of the MR1 α2-helix. Further, the two side-chains
lean toward and form H-bonds with Arg9 and Arg94 that protrude
from the base of the MR1 A′-pocket. Changing the terminal
carboxylic acid group of DB28 for an ester in NV18.1 causes no
major structural changes within the MR1 pocket between both
complexes. Collectively, a pattern of intermolecular hydrophobic
and polar interactions is formed between DB28/NV18.1 ligands
and the MR1 A′-pocket that sequester the ligands inside the cleft.
No direct or water-mediated contacts were observed between the
DB28/NV18.1 ligands and any of the TCR CDRα and CDRβ
loops (Fig. 9 I–K), in agreement with the inability of these com-
pounds to bind to the MAIT TCR (Fig. 8) and the capacity of
DB28 to activate MAIT cells (Fig. 6).
Discussion
During the past 7 y, several MAIT cell agonists and inhibitors
have been identified (23, 24, 26). Stimulatory microbial ligands
are characterized by the presence of a ribityl moiety, while their
potency generally correlates with the formation of a Schiff base
with Lys43 in the MR1 A′-pocket (38, 39). Formation of the
Schiff base is thought to be the key molecular trigger for MR1
translocation to the cell surface, which is transiently observed
upon ligand exposure (20). Through an in silico screen, we have
identified additional MR1-binding ligands and now report the
identity of a ligand that down-regulates MR1 cell surface ex-
pression. Unlike 5-OP-RU or Ac-6-FP, exposure to DB28 does
not lead to MR1 translocation to the cell surface, and in primary
monocytes, B cells, and both myeloid and B cell lines, it reduces
MR1 basal levels of expression. Using epithelial cells expressing
MR1 fused to GFP and intracellular staining for total MR1
proteins, we demonstrated that MR1 molecules are not degraded;
rather, they are retained intracellularly in an EndoH-sensitive
compartment, likely the ER/early Golgi. Consequently, DB28 is
able to competitively inhibit MAIT cell activation by antigen-
presenting cells pulsed with strong and weak synthetic agonists
or infected with bacillus Calmette-Guérin or E. coli, bacteria that
are both able to synthesize vitamin B2 metabolites that are strong
MAIT cell agonists. Down-regulation of MR1 cell surface ex-
pression is observed with two monoclonal antibodies, recognizing
different epitopes of correctly folded MR1 molecules, in agreement
with the lack of complete maturation of MR1 molecules. The effect
of DB28 is specific for MR1 molecules, as no down-regulation of
MHC class I or CD1d molecules is observed. We also observed a
trend of preferential inhibition of newly synthesizedMR1molecules,
as demonstrated by lower MR1 down-regulation in the presence of
the protein synthesis inhibitor cycloheximide or in cells expressing a
doxycycline-inducible MR1 construct. This result suggests the exis-
tence of different compartments within the ER/early Golgi for dis-
tribution of MR1 ligands and might indicate differential association
of MR1-loaded molecules with chaperones; for example, pro-
teins of the peptide-loading complex. Thus, DB28-like molecules
represent important tools for unraveling the molecular mecha-
nisms of MR1-dependent antigen presentation. We investigated
whether DB28 could be used in vivo to inhibit agonist-dependent
MAIT cell activation. Despite the molar excess of DB28, we did
not observe any inhibitory effect, likely because of the short half-
life of the loaded complexes. Indeed, when murine bone marrow
DC were used as antigen-presenting cells, DB28 could compete
the activity of 5-OP-RU, thus ruling out a species-specific effect.
Structural studies confirmed the ability of DB28 to bind within
the MR1 A′ pocket, with an overall topology reminiscent of
5-OP-RU. As predicted from its molecular structure, DB28 does
not form a Schiff base with Lys43 in the MR1 A′ pocket. How-
ever, it is stabilized by a network of hydrophobic interactions and
hydrogen bonds with the charged arginine residues. The lack of
any inhibitory effect on Lys43Ala mutant MR1 molecules might
be explained by the rapid egress of these molecules from the ER
in the absence of any exogenous ligand (20). Other MR1 ligands
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(and weaker MAIT cell agonists) have been described that also
lack the ability to form a Schiff base with Lys43; these include
ribityl lumazines (22, 23) and diclofenac (26). While our results
confirm and extend the observation that MR1 molecules are
loaded in the ER (20) and the need for a Schiff base to trigger
MR1 release to the cell surface, they also suggest that weaker,
non-Schiff base-forming ligands may be loaded on the cell sur-
face or in the recycling compartment. The ester analog of DB28,
NV18.1, is less potent than DB28 in downregulating MR1 mol-
ecules. Consistently, the crystal structure of NV18.1-loaded MR1
molecules indicates that the extra methyl group in NV18.1 might
impart more flexibility on the complex. Neither DB28 nor
NV18.1 form direct contacts with the MAIT TCR, in agreement
with their inability to activate MAIT cells in cellular assay, and
consistent with the low-affinity binding of two MAIT TCRs to
MR1 complexes bound to either DB28 or NV18.1.
Down-regulation of antigen-presenting molecules is a well-
known strategy used by pathogens to evade MHC and CD1d-
restricted T cell responses (40–42). Although to date we have not
identified any microbial metabolite similar to DB28, we suggest
that microbes may use evasion strategies targeting MR1 mole-
cules, given the abundance of MAIT cells and their antimicrobial
function (43). Similarly, it is tempting to speculate that self
molecules similar to DB28 may physiologically regulate MR1
transit through the cell. Indeed, changes in cellular metabolites,
for example, during neoplastic transformation, could potentially
interfere with MR1 trafficking and modulate MAIT cell function
in the tumor microenvironment.
In conclusion, we have identified a compound able to com-
petitively down-regulate MR1 cell surface expression that may
prove to be a useful tool compound for in vivo modulation of
MAIT cell function. We have also identified additional
MAIT cell agonists, which, similar to diclofenac (26), lack a
ribityl moiety, and like lumazines (24), they are not predicted to
form Schiff bases. Although weaker agonists than vitamin B2
intermediates, these compounds could be the starting point for
structure-activity studies aimed at designing novel ligands that
drive MAIT cell-dependent DC and B cell maturation (9, 44, 45).
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Materials and Methods
Medium and Reagents. The complete medium (CM) used throughout was
RPMI 1640 (Gibco) for THP1 (ATCC), DMEM (Gibco) for BEAS2B, and IMDM
(Gibco) for humanMAIT cells. CMwas supplemented with 2 mM L-glutamine,
1% nonessential amino acids, 1% sodium pyruvate, 1% pen/strep, 5 × 10−5
2ME (all from Gibco), and serum: 10% FCS (Sigma) or 5% human AB Serum
(Sigma) for MAIT cells. MAIT cell medium was supplemented with 1,000
U/mL recombinant human IL-2, produced in our laboratory, as previously
described (9).
THP-1 cells (ATCC) and THP-1 overexpressing MR1 were maintained in CM.
THP1 MR1 KO were previously described (36). THP1 cells were transduced
with lentiviral particles generated in 293T cells transfected with lentiviral
vectors encoding for full-length human MR1 (GenBank AJ249778.1), MR1
K43A (20), or GPI-linked MR1 (using the GPI sequence described in ref. 46).
BEAS2B WT cells were grown in DMEM supplemented with 10% heat-
inactivated FBS (Gemini Bio-products) and 3.5 mM L-glutamine (Gibco).
BEAS2B MR1 KO expressing doxycycline-inducible MR1 was previously de-
scribed (34, 35).
Bacillus Calmette-Guérin (gift from Peter Sander) was grown in Mid-
dlebrook 7H9 broth supplemented with Middlebrook ADC (Thermo Fisher
Scientific) and 0.2% glycerol. The bacteria were frozen down at 1.34 × 109
CFU/mL, and thawed aliquots were passaged 10 times through a 27G syringe
before infection. DH5α E. coli bacteria (Thermo Fisher) were grown over-
night to stationary phase in Luria broth, extensively washed in PBS, and
diluted to an OD600 of 0.5 (equivalent to about 400 million bacteria/mL).
Acetyl-6-FP was purchased from Schircks laboratories and was resuspended
in DMSO at 20 mg/mL. 5-A-RU was synthesized as described in the supple-
mentary methods and was combined with 50 μMmethylglyoxal (MG; Sigma)
before each assay to obtain 5-OP-RU. MG was used alongside DMSO as a
negative control in each stimulation assay. DB28 was purchased from
Vitaslab.com (product STK870291) and resuspended in DMSO at 10 mg/mL.
Cycloheximide and doxycycline were purchased from Sigma and resuspended in
DMSO. All compounds were stored in small aliquots at −80 °C, protected
from light.
Generation of MAIT Cells and Antigen-Presenting Cells. Blood was obtained
from the UK National Blood Service. Human MAIT cells were isolated by cell
sorting CD2 MACS enriched leukocytes with CD161 and Vα7.2 antibodies
(Biolegend). In some experiments, antibodies to TRBV20.1 (Miltenyi) or
TRBV13S2 (cone H132, Biolegend) were added to sort MAIT cell subsets.
MAIT cells were grown for 3 wk in CM supplemented with IL-2. iNKT cells
were generated and maintained as described (47).
The MR1-restricted CD8+ TRAV1-2+ T cell clone D426-G11 was previously
described (48).
Jurkat expressing MAIT TCRs have been previously described (29).
THP-1 MR1-HA cells were generated transducing THP-1 cells with a len-
tivirus encoding for MR1-HA tagged molecules, cloned in the lentiviral
vectors pHR-SIN with the following primers: forward: taaccgAGATCTcca
ccatgggggaactgatggcgttcc; reverse: (5′-3′) gctaaGCGGCCGCtcaAGCGTAAT
CTGGAACATCGTATGGGTAtcgatctggtgttggaa.
Stimulation Assays. THP-1 cells were plated at 50,000 cells/well in 96-well
U-bottom plates in CM and incubated with MAIT cells (20,000 cells/well, in
triplicate) in the presence or absence of different concentrations of DB19,
5-OP-RU, and DB28. DB28 (20 μg/mL) was added 2 h before 5-OP-RU unless
otherwise stated. MAIT cell activation was assessed by IFN-γ ELISA (antibodies
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from Becton Dickinson) on supernatants harvested after 16 h. In some ex-
periments, THP1 cells were incubated with 10 μM cycloheximide (Sigma) to
inhibit protein synthesis, starting 30 min before addition of the ligands. In
some experiments, THP1 cells were pulsed with the indicated concentrations
of αGalCer (47) and incubated with iNKT cells at the same Effector:Target ratio
described here.
BEAS2B WT cells were infected overnight with bacillus Calmette-Guérin at
the indicated multiplicity of infection (MOI), harvested, washed, and 10,000
cells/well were plated in ELISPOT plates precoated with IFN-γ capture anti-
body (Mabtech, 1-DIK). Cells were treated with DB28 (20 μg/mL final con-
centration) or DMSO for 2 h before addition of phytohemagglutinin and
10,000 cells/well of the MAIT cell clone D426-G11, used from frozen. ELI-
SPOTs were performed in RPMI (Gibco) supplemented with 3.5 mM L-glu-
tamine (Gibco), 10% heat-inactivated human serum, and 50 μg/mL
gentamycin (Gibco). IFN-γ spot-forming units were enumerated on an AID
ELISPOT reader after development with an ALP antibody (Mabtech, 7-B6-1-
ALP) after overnight incubation.
MR1 Up-Regulation Assay. THP1 cells overexpressing MR1 and CD1d were
incubated for 5 to 7 h or overnight with 20 μg/mL of DB28/NV18.1, 5 μg/mL
5-OP-RU, or 1 μg/mL acetyl-6-FP. Cells were harvested and stained for cell
surface MR1 (clone 26.5, Biolegend; clone 8F2F9, purified in house) or CD1d
(clone 42.1, Biolegend). In some experiments, cells were washed and chased
for the indicated amount of time before staining. Total MR1 contents were
determined on fixed and permeabilized cells (Foxp3 kit; Thermo Fisher) with
the rabbit MR1 polyclonal antibody (Proteintech, cat n 13260-1-AP), or with
the anti-HA mouse monoclonal antibody (clone 2–2.2.14; Thermo Fisher)
followed by PE-labeled anti-rabbit or anti-mouse antibodies (Thermo Fisher).
Samples were acquired on a ×50 BD symphony machine and analyzed with
Flowjo 10. Viability was assessed with live/dead staining (Aqua or near in-
frared), according to the manufacturer’s instructions (Thermo Fisher).
Whole Blood Assay. Freshly drawn blood was distributed in 5-mL poly-
propylene conical tubes (BD Falcon). One milliliter of blood was activated
with 5-OP-RU (10 μg/mL) or E. coli at the indicated MOI in the presence or
absence of DB28 (100 μg/mL). After overnight stimulation, cells were stained
in Brilliant violet buffer (BD) with the following antibodies: BUV661 CD3
(UCHT1; BD), PE/Dazzle CD137 (VI C-7, Biolegend), antigen-presenting cell
CD161 (HP-3G10, Biolegend), BV605 Vα7.2 (3C10, Biolegend), and BV510
CD19 (HIB19, Biolegend). Samples were acquired on a ×50 BD Symphony
machine and analyzed with FlowJo 10. Viability was assessed with live/dead
Aqua staining, according to the manufacturer’s instructions (Thermo Fisher).
E. coli (DH5a; Thermo Fisher) was grown overnight in Luria broth medium
and after extensive washing in PBS, OD600 was measured. An OD600 = 1 was
considered equivalent to 5 × 108 bacteria/mL
BEAS2B Tet MR1-GFP Assays. Cells were plated in 6-well plates at 70% con-
fluence. MR1 expression was induced with 2 μg/mL doxycycline (Sigma) 16 to
24 h before addition of the ligands. Ligands were incubated either 7 h or
overnight, in the presence or absence of doxycycline, before harvesting the
cells for FACS analysis.
Statistical Analysis. Statistical analyses were performed with GraphPad Prism
software, version 8. Comparisons were performed with t test, and differences
with P < 0.05 were deemed significant.
MR1 Docking. Constraints imposed during docking included the presence of
an aromatic ring at a distance suitable for aromatic interactions with Y7. Four
hydrogen-bonding interactions were required out of the selected interac-
tions formed by cocrystallized ligands in the complex structures used for the
virtual screening. Poses lacking aromatic stacking interactions with Y7 resi-
due of MR1 were excluded. Out of the top-scoring poses, the selection was
based on favorable interactions with MR1/TCR residues and the presence of
suboptimal contacts. In the case of compounds with acceptable poses, only
the most favorable pose was included in the final selection.
Protein Production and SPR Measurements. Soluble A-F7 MAIT TCR (TRAV1-2-
TRBV6-1), #6 (TRAV1-2-TRBV6-4) TCR, and human MR1-β2m-Ag were refol-
ded from inclusion bodies and purified as described (22, 25). All SPR mea-
surements were conducted in duplicate (n = 2) on a BIAcore 3000 instrument, as
described previously (25, 37). For extended description, see SI Appendix,
Supplemental Experimental Procedures.
Crystallization, Structure Determination, and Refinement. A-F7 TCR was mixed
with MR1-β2m-Ag in 1:1 ratio, and ternary complex crystals were obtained
by hanging drop crystallization, as established previously (22). Data were
collected at the Australian Synchrotron Facility, processed and refined with
standard software packages. For an extended description, see SI Appendix,
Supplemental Experimental Procedures.
Accession Numbers. The coordinates of the ternary complexes of MAIT A-F7
TCR-MR1-DB28 and TCR-MR1-NV18.1 have been deposited in the Protein
Data Bank under accession codes 6PVC and 6PVD.
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